**
Recent findings suggest that GLP-1 medications, commonly used for weight management and diabetes, may be associated with a lower risk of certain cancers. With semaglutide becoming increasingly accessible and prices falling—thanks in part to generic versions arriving at Canadian pharmacies—this research offers a promising avenue for future health strategies. Presented at the American Society of Clinical Oncology meeting in Chicago, the studies indicate that patients using GLP-1 drugs experience not only reduced cancer incidence but also improved treatment responses compared to their non-user counterparts.
Groundbreaking Findings on Cancer Risk
Dr. Judith Bray, the vice-president of research at the Canadian Cancer Society, has highlighted the transformative potential of these findings, noting that the scientific community is only now awakening to the implications of GLP-1 drugs in cancer prevention. “These rumbling or smoking guns have been firing off for well over a year now about this possibility,” she stated, emphasizing the urgency for further investigation.
One notable study presented at the conference involved over 161,000 patients, predominantly obese individuals without diabetes or a history of obesity-related cancers. Participants were divided into two groups: one receiving GLP-1 medications and the other receiving standard dietary consultations. The results were compelling; those on GLP-1 treatment exhibited a staggering 41 per cent lower risk of developing obesity-related cancers over the follow-up period.
Implications for Breast Cancer
Adding to the conversation, a study published in the JCO Oncology Practice on June 2 indicated a significant correlation between GLP-1 treatments and a reduced incidence of breast cancer. The research, which examined data from over 110,000 women aged 45 to 80, found that those prescribed GLP-1 medications had a 35 per cent lower risk of breast cancer compared to those who did not take these drugs. After adjusting for various factors such as age, race, and body mass index, the odds of developing breast cancer were still significantly lower—about 31 per cent—among GLP-1 users.
Lead researcher Dr. Elizabeth McDonald underscored the observational nature of the study, cautioning that while it does not establish a definitive causal link, it contributes to an expanding body of evidence warranting further exploration into the role of these weight-loss drugs as potential cancer prevention tools.
The Need for Further Research
Despite the promising results, experts like Dr. Bray and Kimberly Carson, CEO of Breast Cancer Canada, advocate for more comprehensive research in Canada to better understand the implications of GLP-1 drugs. Carson expressed optimism about the findings but stressed the importance of gathering Canadian data, suggesting that Canada has the potential to conduct meaningful studies in this area.
As statistics reveal a troubling rise in obesity rates among Canadians—68 per cent of adults aged 18 to 79 classified as overweight or obese from 2022 to 2024, up from 60 per cent pre-pandemic—the urgency for effective interventions becomes clear. With breast cancer projected to remain the most commonly diagnosed cancer among women by 2026, the potential of GLP-1 medications offers a glimmer of hope.
Why it Matters
The exploration of GLP-1 medications as a dual-purpose treatment—addressing both obesity and cancer risk—could revolutionise public health strategies in Canada and beyond. As we grapple with escalating obesity rates and the associated health challenges, these findings may pave the way for innovative approaches in cancer prevention and treatment. The opportunity to leverage existing medications for broader health benefits underscores the critical need for ongoing research, collaboration, and investment in this promising field.
